All In Biotech

Drug Trial Radar · NCT02332668

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

370

Planned (sponsor's estimate)

Start

Mar 19, 2015

Primary completion

Feb 2, 2028

Study completion Feb 2, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away. With Amendment 8, enrollment of participants with solid tumors and participants 6 months to under 12 years old with melanoma were closed. With Amendment 13, enrollment was closed for participants with relapsed refractory classical Hodgkin lymphoma (rrCHL), microsatellite instabilty-high (MSI-H) solid tumors, tumor-mutational burden-high (TMB-H) solid tumors, and participants 12 years old to \<18 years old with advanced melanoma.

Conditions

  • Melanoma
  • Lymphoma
  • Solid Tumor
  • Classical Hodgkin Lymphoma
  • Microsatellite-instability-high Solid Tumor

Interventions

  • PembrolizumabBiological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors and Other Lymphoma Version 1.1 (RECIST 1.1) per Site Assessment (Each Disease Indication Evaluated Separately)Time frame: Up to 2 years
  2. ORR by RECIST 1.1 per Site Assessment for MSI-H or TMBH Solid Tumors (Each Cohort Evaluated Separately)Time frame: Up to 2 years
  3. ORR by International Working Group (IWG) Response Criteria (Cheson, 2007) per Blinded Independent Central Review (BICR) Assessment for rrcHL CohortTime frame: Up to approximately 2 years
  4. Number of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1 (Up to 21 days)
  5. Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to 27 months
  6. Number of Participants Discontinuing Study Drug Due to AEsTime frame: Up to 2 years

Locations

15 sites in 9 countries. Site status is shown where the registry gives one.

  • Call for Information (Investigational Site 0019)

    Aurora, Colorado · Recruiting

  • Call for Information (Investigational Site 0024)

    Chicago, Illinois · Recruiting

  • Call for Information (Investigational Site 0026)

    Boston, Massachusetts · Recruiting

  • Call for Information (Investigational Site 0031)

    New York, New York · Recruiting

  • Call for Information (Investigational Site 0070)

    Fargo, North Dakota · Recruiting

  • Call for Information (Investigational Site 0071)

    Sioux Falls, South Dakota · Recruiting

  • Call for Information (Investigational Site 0054)

    Dallas, Texas · Recruiting

  • MSD Brasil

    São Paulo, Brazil · Recruiting

  • MSD France

    Paris, France · Recruiting

  • MSD Sharp & Dohme GmbH

    München, Germany · Recruiting

  • MSD Italia S.r.l.

    Rome, Italy · Recruiting

  • Merck Sharp & Dohme Lda.

    Paço de Arcos, Portugal · Recruiting

  • MSD Korea LTD

    Seoul, South Korea · Recruiting

  • MSD Sweden

    Stockholm, Sweden · Recruiting

  • Merck Sharp & Dohme Ltd.

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.